Arrowhead Pharmaceuticals Inc
NASDAQ:ARWR

Watchlist Manager
Arrowhead Pharmaceuticals Inc Logo
Arrowhead Pharmaceuticals Inc
NASDAQ:ARWR
Watchlist
Price: 18.54 USD 1.42% Market Closed
Market Cap: 2.3B USD
Have any thoughts about
Arrowhead Pharmaceuticals Inc?
Write Note

Arrowhead Pharmaceuticals Inc
Cash from Financing Activities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Arrowhead Pharmaceuticals Inc
Cash from Financing Activities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash from Financing Activities CAGR 3Y CAGR 5Y CAGR 10Y
Arrowhead Pharmaceuticals Inc
NASDAQ:ARWR
Cash from Financing Activities
$481.6m
CAGR 3-Years
247%
CAGR 5-Years
49%
CAGR 10-Years
10%
Abbvie Inc
NYSE:ABBV
Cash from Financing Activities
-$2.8B
CAGR 3-Years
45%
CAGR 5-Years
25%
CAGR 10-Years
1%
Gilead Sciences Inc
NASDAQ:GILD
Cash from Financing Activities
-$6.8B
CAGR 3-Years
0%
CAGR 5-Years
4%
CAGR 10-Years
-3%
Amgen Inc
NASDAQ:AMGN
Cash from Financing Activities
-$5.3B
CAGR 3-Years
0%
CAGR 5-Years
21%
CAGR 10-Years
N/A
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Cash from Financing Activities
-$1.2B
CAGR 3-Years
1%
CAGR 5-Years
-55%
CAGR 10-Years
N/A
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Cash from Financing Activities
-$1.5B
CAGR 3-Years
-55%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Arrowhead Pharmaceuticals Inc
Glance View

Market Cap
2.3B USD
Industry
Biotechnology

Arrowhead Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development of medicines that treat intractable diseases by silencing the genes that cause them. The company is headquartered in Pasadena, California and currently employs 329 full-time employees. The firm uses a portfolio of ribonucleic acid (RNA) chemistries and modes of delivery, the Company's therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. The firm is focused on developing drugs for diseases with a genetic basis, characterized by the overproduction of one or more proteins. The firm's pipeline includes ARO-APOC3 for hypertriglyceridemia, ARO-ANG3 for dyslipidemia, ARO-HSD for liver disease, ARO-ENaC for cystic fibrosis, ARO-HIF2 for renal cell carcinoma, ARO-DUX4 for facioscapulohumeral muscular dystrophy, ARO-LUNG2 for chronic obstructive pulmonary disorder, and ARO-COV for the coronavirus that causes COVID-19 and other possible future pulmonary-borne pathogens.

ARWR Intrinsic Value
27.97 USD
Undervaluation 34%
Intrinsic Value
Price

See Also

What is Arrowhead Pharmaceuticals Inc's Cash from Financing Activities?
Cash from Financing Activities
481.6m USD

Based on the financial report for Jun 30, 2024, Arrowhead Pharmaceuticals Inc's Cash from Financing Activities amounts to 481.6m USD.

What is Arrowhead Pharmaceuticals Inc's Cash from Financing Activities growth rate?
Cash from Financing Activities CAGR 10Y
10%

Over the last year, the Cash from Financing Activities growth was 90%. The average annual Cash from Financing Activities growth rates for Arrowhead Pharmaceuticals Inc have been 247% over the past three years , 49% over the past five years , and 10% over the past ten years .

Back to Top